ROIV
NASDAQ · Biotechnology
Roivant Sciences Ltd
$27.36
+0.49 (+1.82%)
Financial Highlights (FY 2026)
Revenue
29.22M
Net Income
-172,768,919
Gross Margin
96.9%
Profit Margin
-592.0%
Rev Growth
-19.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 96.9% | 96.9% | 53.5% | 53.5% |
| Operating Margin | -3,442.6% | -3,098.4% | -4.7% | -4.6% |
| Profit Margin | -592.0% | -562.4% | -5.1% | -4.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 29.22M | 36.21M | 2.76B | 2.29B |
| Gross Profit | 28.30M | 35.07M | 1.47B | 1.22B |
| Operating Income | -1,005,932,354 | -1,121,857,643 | -129,388,409 | -105,547,959 |
| Net Income | -172,768,919 | -192,679,091 | -140,854,131 | -104,632,272 |
| Gross Margin | 96.9% | 96.9% | 53.5% | 53.5% |
| Operating Margin | -3,442.6% | -3,098.4% | -4.7% | -4.6% |
| Profit Margin | -592.0% | -562.4% | -5.1% | -4.6% |
| Rev Growth | -19.3% | -19.3% | -1.7% | -7.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.19B | 7.29B |
| Total Equity | — | — | 12.91B | 14.47B |
| D/E Ratio | — | — | 0.56 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -985,533,375 | -1,160,169,400 | -182,068,335 | -161,653,425 |
| Free Cash Flow | — | — | -125,369,781 | -83,019,830 |